The transcriptome association study has helped prioritize many causal genes for detailed study and thus further helped the development of many therapeutic strategies for multiple diseases. How- ever, prioritizing the causal gene only does not seem always to be able to offer sufficient guidance to the downstream analysis. Thus, in this paper, we propose to perform the association studies from another perspective: we aim to prioritize genes with a tradeoff between the pursuit of the causality evidence and the interest of the genes in the pathway. We introduce a new method for transcriptome association study by incorporating the information of gene regulatory networks. In addition to directly building the regularization into variable selection methods, we also expect the method to report p-values of the associated genes so that these p-values have been empirically proved trustworthy by geneticists. Thus, we introduce a high-dimension variable selection method with the following two merits: it has a flexible modeling power that allows the domain experts to consider the structure of covariates so that prior knowledge, such as the gene regulatory network, can be integrated; it also calculates the p-value, with a practical manner widely accepted by geneticists, so that the identified covariates can be directly assessed with statistical guarantees. With simulations, we demonstrate the empirical strength of our method against other high-dimension variable selection methods. We further apply our method to Alzheimer’s disease, and our method identifies interesting sets of genes.